This company listing is no longer active
1LV Stock Overview
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Satsuma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$8.05 |
| 52 Week Low | US$0.58 |
| Beta | 0.10 |
| 1 Month Change | 7.29% |
| 3 Month Change | 18.39% |
| 1 Year Change | -66.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1LV | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.6% | 3.9% | 2.0% |
| 1Y | -67.0% | -28.2% | 2.0% |
Return vs Industry: 1LV underperformed the German Pharmaceuticals industry which returned -10.5% over the past year.
Return vs Market: 1LV underperformed the German Market which returned -5.5% over the past year.
Price Volatility
| 1LV volatility | |
|---|---|
| 1LV Average Weekly Movement | 16.4% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1LV's share price has been volatile over the past 3 months.
Volatility Over Time: 1LV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 25 | John Kollins | www.satsumarx.com |
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company’s product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc. Fundamentals Summary
| 1LV fundamental statistics | |
|---|---|
| Market cap | €33.83m |
| Earnings (TTM) | -€60.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 1LV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1LV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.83m |
| Earnings | -US$64.83m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1LV perform over the long term?
See historical performance and comparison